Adage Capital Partners Gp, L.L.C. Terns Pharmaceuticals, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.54 - $8.2 $567,500 - $1.02 Million	125,000 Added 14.71%	975,000 $6.64 Million
Q1 2024 May 15, 2024	SELL	$4.86 - $8.19 $972,000 - $1.64 Million	-200,000 Reduced 19.05%	850,000 $5.58 Million
Q4 2023 Feb 14, 2024	BUY	$3.37 - $6.86 $3.2 Million - $6.52 Million	950,000 Added 950.0%	1,050,000 $6.81 Million
Q3 2023 Nov 14, 2023	SELL	$4.7 - $8.55 $235,000 - $427,500	-50,000 Reduced 33.33%	100,000 $503,000
Q2 2023 Aug 14, 2023	BUY	$7.35 - $13.29 $1.1 Million - $1.99 Million	150,000 New	150,000 $1.31 Million

167

78.3M

580K

454K

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $216M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.